NCT06054451

Brief Summary

There is a need to re-evaluate the patients classified as NCPH and determine whether the new histological classification proposed by the VALDIG applies to the Indian scenario. We intend to identify the patient cohorts who have been diagnosed as NCPH, NCPF, EHPVO, hepatic venous outlet tract obstruction (HVOTO), Veno-occlusive disease (VOD) and sinusoidal obstruction syndrome (SOS) based on their liver biopsy, endoscopy, HVPG, and radiology reports. These patients will be screened to find the patients who fit the diagnosis of PSVD. It is important to establish whether the new definition of PSVD is relevant to the Indian population and establish the usefulness of invasive tests like liver biopsy in diagnosing the disease. The patient cohorts meeting diagnosis of INCPH will be compared with those meeting the new diagnosis of PSVD. The investigators will describe the clinical (demographic, clinical risk factors, socioeconomic status), etiological (associated conditions, coagulation disorders medication use, genetic risk factors), imaging (based on ultrasound Doppler imaging or cross- sectional imaging), endoscopic, fibrosis tests (using non-invasive tests), and the histopathology of the patients who fulfil the criteria of PSVD.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
210

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2023

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

August 11, 2023

Completed
2 months until next milestone

First Posted

Study publicly available on registry

September 26, 2023

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2024

Completed
Last Updated

April 25, 2024

Status Verified

April 1, 2024

Enrollment Period

10 months

First QC Date

August 11, 2023

Last Update Submit

April 23, 2024

Conditions

Keywords

Porto-sinusoidal vascular diseaseBudd Chiari Syndromextrahepatic portal venous obstructionPortal HypertensionNon-Cirrhotic Portal Fibrosis

Outcome Measures

Primary Outcomes (1)

  • To describe the clinical presentation of patients with a diagnosis of PSVD.

    Listing clinical presentation (signs and symptoms) of patients with PSVD (variceal bleeding, pain, ascites, sensation of lump, etc)

    Day 0

Secondary Outcomes (6)

  • Radiological description of patients with PSVD based on CT venography

    Day 0

  • Radiological description of patients with PSVD based on Doppler Ultrasound

    Day 0

  • Histopathological features and subtypes of the PSVD spectrum in patients from India with assessment of parenchyma, vessels, portal triad and fibrosis

    Day 0

  • Ratio of liver stiffness and splenic stiffness using transient elastography in diagnosis of PSVD

    Day 0

  • Change in biomarkers like Factor VIII Ag or vWF in diagnosis of PSVD

    Day 0

  • +1 more secondary outcomes

Eligibility Criteria

Age12 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients diagnosed as NCPF, EHPVO, HVOTO, SOS, VOD will be screened for reclassification based on diagnostic criteria for PSVD

You may qualify if:

  • Patients of 12-70 years, either gender with clinical, pathological radiological diagnosis of NCPH

You may not qualify if:

  • Any patients having Cirrhosis based on clinical, pathological, or radiological diagnosis
  • Any patients having active malignancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dr. Madhumita Premkumar

Sector-12, Chandigarh, 160012, India

RECRUITING

MeSH Terms

Conditions

Hypertension, PortalBudd-Chiari SyndromeIdiopathic Noncirrhotic Portal HypertensionHepatic Veno-Occlusive Disease

Condition Hierarchy (Ancestors)

Liver DiseasesDigestive System DiseasesVenous ThrombosisThrombosisEmbolism and ThrombosisVascular DiseasesCardiovascular Diseases

Study Officials

  • Dr Madhumita Premkumar, DM

    Post Graduate Institute of Medical Education and Research, Chandigarh

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Dr Madhumita Premkumar, DM

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
ASSOCIATE PROFESSOR

Study Record Dates

First Submitted

August 11, 2023

First Posted

September 26, 2023

Study Start

August 1, 2023

Primary Completion

June 1, 2024

Study Completion

June 1, 2024

Last Updated

April 25, 2024

Record last verified: 2024-04

Data Sharing

IPD Sharing
Will not share

Locations